NASDAQ:SRDX
SurModics Stock News
$32.16
-0.160 (-0.495%)
At Close: May 10, 2024
Surmodics (SRDX) Rallies on FDA Approval for SurVeil DCB
07:18am, Wednesday, 21'st Jun 2023
Surmodics' (SRDX) SurVeil DCB is indicated to treat percutaneous transluminal angioplasty in peripheral artery disease patients. Abbott will initiate commercialization of SurVeil DCB, per a deal with
Strength Seen in SurModics (SRDX): Can Its 16.1% Jump Turn into More Strength?
03:33am, Wednesday, 21'st Jun 2023
SurModics (SRDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Surmodics' (SRDX) Receipt of New FDA Nod to Boost Patient Care
12:20pm, Friday, 16'th Jun 2023
Surmodics' (SRDX) receipt of FDA's clearance is expected to expand the treatment range of the Pounce platform and serve a wider patient pool.
Why Shares of Surmodics Soared on Tuesday
01:11pm, Tuesday, 13'th Jun 2023
Surmodics makes coatings for medical devices and manufactures chemicals for diagnostic immunoassay tests. The company said it hopes to get approval for its drug-coated balloon vascular device by the f
Top 5 Health Care Stocks That Could Blast Off In May - Coherus BioSciences (NASDAQ:CHRS), Intercept Pharma (NASDAQ:ICPT)
08:56am, Friday, 26'th May 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Surmodics (SRDX) Q2 Earnings Top Estimates, FY23 View Revised
12:10pm, Thursday, 27'th Apr 2023
Surmodics (SRDX) reports a solid fiscal second-quarter top line on the back of robust Medical Device revenues.
Surmodics, Inc (SRDX) Q2 2023 Earnings Call Transcript
12:24pm, Wednesday, 26'th Apr 2023
Surmodics, Inc (SRDX) Q2 2023 Earnings Call Transcript.
SurModics (SRDX) Reports Q2 Loss, Tops Revenue Estimates
09:54am, Wednesday, 26'th Apr 2023
SurModics (SRDX) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.22 per share a year ago.
Here's Why You Should Retain Surmodics (SRDX) Stock for Now
12:14pm, Thursday, 06'th Apr 2023
Investors continue to feel optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
Surmodics (SRDX) Gets FDA's Formal Feedback About SurVeil DCB
09:59am, Wednesday, 29'th Mar 2023
Surmodics' (SRDX) receipt of the FDA's positive formal feedback regarding its PMA application for the SurVeil DCB looks promising.
SurModics (SRDX) Moves 5.4% Higher: Will This Strength Last?
09:58am, Friday, 17'th Mar 2023
SurModics (SRDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in
Surmodics (SRDX) Q1 Earnings Top Estimates, FY23 View Revised
11:18am, Tuesday, 07'th Feb 2023
Surmodics (SRDX) reports a solid fiscal first quarter top line on the back of robust Medical Device revenues.
Surmodics, Inc. (SRDX) Q1 2023 Earnings Call Transcript
09:41pm, Monday, 06'th Feb 2023
Surmodics, Inc. (NASDAQ:SRDX ) Q1 2023 Earnings Conference Call February 6, 2023 5:00 PM ET Company Representatives Gary Maharaj - President, Chief Executive Officer Tim Arens - Chief Financial Office
SurModics (SRDX) Reports Q1 Loss, Tops Revenue Estimates
07:34pm, Monday, 06'th Feb 2023
SurModics (SRDX) delivered earnings and revenue surprises of 21.88% and 3.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Surmodics to Report First Quarter of Fiscal 2023 Financial Results on February 6
08:30am, Thursday, 26'th Jan 2023
EDEN PRAIRIE, Minn.--( BUSINESS WIRE )--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that first
